What you need to know Adrenal insufficiency is the inadequate production of the hormone cortisol from the adrenal glands. Global prevalence ranges from 0.4/100 000 (South Korea) to 15-22/100 000 ...

As Healio previously reported, in the main results of FINE-HEART, a pooled analysis of the FINEARTS-HF, FIDELIO-DKD and FIGARO-DKD trials of the nonsteroidal, selective mineralocorticoid receptor ...

"Current therapeutic approaches targeting aldosterone, such as mineralocorticoid receptor antagonists, have limitations -- among them, compensatory increases in serum aldosterone levels ...

Figure 1: Generation of mice deficient for Gr in the nervous system. Figure 2: Mice lacking Gr in the nervous system display symptoms characteristic of Cushing syndrome including reduced size ...

The loss of libido can also be related to low testosterone levels, which may be remediable through supplementation with exogenous testosterone.

Eli Lilly's dual GLP-1/GIP agonist tirzepatide has been shown to reduce the risk of worsening disease in people with heart failure and obesity in a phase 3 trial, the first to show a benefit on ...

At the time the licensing agreement was signed in October 2023, ocedurenone – an oral non-steroidal mineralocorticoid receptor antagonist (nsMRA) – was being tested in a phase 3 trial in ...

Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. Primary cilia are cell signalling and ...

2 University College London Hospitals NHS Foundation Trust, London, UK Background and aims Mineralocorticoid receptor antagonists (MRAs) reduce mortality and hospitalisation in heart failure with ...